These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 32163180)

  • 1. Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model.
    Hájek R; Sandecka V; Špička I; Raab M; Goldschmidt H; Beck S; Minařík J; Pavlíček P; Radocha J; Heindorfer A; Jelínek T; Stejskal L; Brožová L; Ševčíková S; Straub J; Pika T; Pour L; Maisnar V; Seckinger A; Hose D
    Br J Haematol; 2020 Jul; 190(2):189-197. PubMed ID: 32163180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of involved/uninvolved free light chain ratio determined by Freelite and N Latex FLC assays for identification of high-risk smoldering myeloma patients.
    Henriot B; Rouger E; Rousseau C; Escoffre M; Sébillot M; Bendavid C; Minvielle S; Avet-Loiseau H; Decaux O; Moreau C
    Clin Chem Lab Med; 2019 Aug; 57(9):1397-1405. PubMed ID: 30973821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.
    Lakshman A; Rajkumar SV; Buadi FK; Binder M; Gertz MA; Lacy MQ; Dispenzieri A; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Kapoor P; Leung N; Go RS; Lin Y; Kourelis TV; Warsame R; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK
    Blood Cancer J; 2018 Jun; 8(6):59. PubMed ID: 29895887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling.
    Wu V; Moshier E; Leng S; Barlogie B; Cho HJ; Jagannath S; Madduri D; Mazumdar M; Parekh S; Chari A
    Blood Adv; 2018 Jun; 2(12):1470-1479. PubMed ID: 29945937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Smoldering multiple myeloma: the role of different scoring systems in identifying high-risk patients in real-life practice.
    Cocito F; Mangiacavalli S; Ferretti VV; Cartia CS; Ganzetti M; Benveuti P; Pompa A; Catalano M; Fugazza E; Landini B; Arcaini L; Corso A
    Leuk Lymphoma; 2019 Dec; 60(12):2968-2974. PubMed ID: 31169049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies.
    Sandecka V; Popkova T; Stork M; Maisnar V; Minarik J; Jungova A; Pavlicek P; Stejskal L; Pospisilova L; Heindorfer A; Obernauerova J; Gregora E; Sykora M; Ullrychova J; Wrobel M; Kessler P; Jelinek T; Kunovszki P; Bathija S; Gros B; Wilbertz S; Cai Q; Lam A; Spicka I
    Blood Cancer J; 2023 Sep; 13(1):153. PubMed ID: 37752128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline serum B-cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma.
    Bujarski S; Goldwater MS; Regidor BS; Jew S; Daniely D; Swift RA; Eades BM; Emamy-Sadr M; Souther E; Li M; Wang C; Xu N; Chen H; Spektor TM; Berenson JR
    Eur J Haematol; 2021 Sep; 107(3):318-323. PubMed ID: 33993536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression.
    Fernández de Larrea C; Isola I; Pereira A; Cibeira MT; Magnano L; Tovar N; Rodríguez-Lobato LG; Calvo X; Aróstegui JI; Díaz T; Lozano E; Rozman M; Yagüe J; Bladé J; Rosiñol L
    Leukemia; 2018 Jun; 32(6):1427-1434. PubMed ID: 29463830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies.
    Visram A; Cook J; Warsame R
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):673-681. PubMed ID: 34889380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testing Mayo Clinic's New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study.
    Tessier C; Allard T; Boudreault JS; Kaedbey R; Éthier V; Fortin F; Pavic M
    Curr Oncol; 2021 May; 28(3):2029-2039. PubMed ID: 34073289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study.
    Sørrig R; Klausen TW; Salomo M; Vangsted AJ; Østergaard B; Gregersen H; Frølund UC; Andersen NF; Helleberg C; Andersen KT; Pedersen RS; Pedersen P; Abildgaard N; Gimsing P;
    Eur J Haematol; 2016 Sep; 97(3):303-9. PubMed ID: 26710662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of smoldering multiple myeloma based on nationwide screening.
    Thorsteinsdóttir S; Gíslason GK; Aspelund T; Rögnvaldsson S; Óskarsson JÞ; Sigurðardóttir GÁ; Þórðardóttir ÁR; Viðarsson B; Önundarson PT; Agnarsson BA; Sigurðardóttir M; Þorsteinsdóttir I; Ólafsson Í; Eyþórsson E; Jónsson Á; Berlanga O; Hultcrantz M; Durie BGM; Löve TJ; Harding S; Landgren O; Kristinsson SY
    Nat Med; 2023 Feb; 29(2):467-472. PubMed ID: 36747117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM).
    Mateos MV; Kumar S; Dimopoulos MA; González-Calle V; Kastritis E; Hajek R; De Larrea CF; Morgan GJ; Merlini G; Goldschmidt H; Geraldes C; Gozzetti A; Kyriakou C; Garderet L; Hansson M; Zamagni E; Fantl D; Leleu X; Kim BS; Esteves G; Ludwig H; Usmani S; Min CK; Qi M; Ukropec J; Weiss BM; Rajkumar SV; Durie BGM; San-Miguel J
    Blood Cancer J; 2020 Oct; 10(10):102. PubMed ID: 33067414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum markers alone can define high-risk smouldering multiple myeloma: new insights from the Czech Myeloma Group model.
    Sørrig R
    Br J Haematol; 2020 Jul; 190(2):137-138. PubMed ID: 32220013
    [No Abstract]   [Full Text] [Related]  

  • 15. Therapeutic Advances in the Management of Smoldering Myeloma.
    Khan R; Zahid U; Kollu V; Jahan N; Ali M; Tricot G; Anwer F
    Am J Ther; 2020; 27(2):e194-e203. PubMed ID: 31842112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Asymptomatic and Treatment-requiring Multiple Myeloma - Data from the Czech Registry of Monoclonal Gammopathies.
    Brozova L; Jarkovský J; Pour L; Minárik J; Jungová A; Gregora E; Spicka I; Maisnar V; Hájek R
    Klin Onkol; 2017; 30(Supplementum2):51-59. PubMed ID: 28903571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
    Ho M; Patel A; Goh CY; Moscvin M; Zhang L; Bianchi G
    Leukemia; 2020 Dec; 34(12):3111-3125. PubMed ID: 33046818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Timing treatment for smoldering myeloma: is earlier better?
    Hernández JÁ; Martínez-López J; Lahuerta JJ
    Expert Rev Hematol; 2019 May; 12(5):345-354. PubMed ID: 30907176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mode of progression in smoldering multiple myeloma: a study of 406 patients.
    Abdallah NH; Lakshman A; Kumar SK; Cook J; Binder M; Kapoor P; Dispenzieri A; Gertz MA; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Lin Y; Kourelis T; Warsame R; Bergsagel L; Rajkumar SV
    Blood Cancer J; 2024 Jan; 14(1):9. PubMed ID: 38228628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients.
    González-Calle V; Mateos MV
    Eur J Intern Med; 2018 Dec; 58():57-63. PubMed ID: 29907380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.